Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H21NO4.ClH.2H2O |
Molecular Weight | 399.866 |
Optical Activity | ( - ) |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.Cl.OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
InChI
InChIKey=TXMZWEASFRBVKY-IOQDSZRYSA-N
InChI=1S/C19H21NO4.ClH.2H2O/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11;;;/h2-4,14,17,21,23H,1,5-10H2;1H;2*1H2/t14-,17+,18+,19-;;;/m1.../s1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H21NO4 |
Molecular Weight | 327.3743 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Naloxone, sold under the brand name Narcan among others, is a medication used to block the effects of opioids, especially in overdose. Naloxone has an extremely high affinity for μ-opioid receptors in the central nervous system (CNS). Naloxone is a μ-opioid receptor (MOR) inverse agonist, and its rapid blockade of those receptors often produces rapid onset of withdrawal symptoms. Naloxone also has an antagonist action, though with a lower affinity, at κ- (KOR) and δ-opioid receptors (DOR). If administered in the absence of concomitant opioid use, no functional pharmacological activity occurs (except the inability for the body to combat pain naturally). In contrast to direct opiate agonists, which elicit opiate withdrawal symptoms when discontinued in opiate-tolerant people, no evidence indicates the development of tolerance or dependence on naloxone. The mechanism of action is not completely understood, but studies suggest it functions to produce withdrawal symptoms by competing for opiate receptor sites within the CNS (a competitive antagonist, not a direct agonist), thereby preventing the action of both endogenous and xenobiotic opiates on these receptors without directly producing any effects itself. When administered parenterally (e.g. intravenously or by injection), as is most common, naloxone has a rapid distribution throughout the body. The mean serum half-life has been shown to range from 30 to 81 minutes, shorter than the average half-life of some opiates, necessitating repeat dosing if opioid receptors must be stopped from triggering for an extended period. Naloxone is primarily metabolized by the liver. Its major metabolite is naloxone-3-glucuronide, which is excreted in the urine. Naloxone is useful both in acute opioid overdose and in reducing respiratory or mental depression due to opioids. Whether it is useful in those in cardiac arrest due to an opioid overdose is unclear. Naloxone is poorly absorbed when taken by mouth, so it is commonly combined with a number of oral opioid preparations, including buprenorphine and pentazocine, so that when taken orally, just the opioid has an effect, but if misused by injecting, the naloxone blocks the effect of the opioid. In a meta-analysis of people with shock, including septic, cardiogenic, hemorrhagic, or spinal shock, those who received naloxone had improved blood flow. Naloxone is also experimentally used in the treatment for congenital insensitivity to pain with anhidrosis, an extremely rare disorder (one in 125 million) that renders one unable to feel pain or differentiate temperatures. Naloxone can also be used as an antidote in overdose of clonidine, a medication that lowers blood pressure.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17149859 |
7.3 nM [IC50] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12747782 |
49.8 nM [IC50] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17388627 |
138.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NARCAN Approved UsePentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only. Launch Date1971 |
|||
Primary | NARCAN Approved UsePentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only. Launch Date1971 |
|||
Primary | NARCAN Approved UsePentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only. Launch Date1971 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28444856/ |
10 mg/kg single, nasal dose: 10 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.83 ng/mL DRUG LABEL https://www.fda.gov/media/95283/download |
4 mg single, nasal dose: 4 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.87 ng/mL DRUG LABEL https://www.fda.gov/media/95283/download |
0.4 mg single, intramuscular dose: 0.4 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
9.62 ng/mL DRUG LABEL https://www.fda.gov/media/95283/download |
8 mg single, nasal dose: 8 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
37.1 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28444856/ |
10 mg/kg single, nasal dose: 10 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.9 ng × h/mL DRUG LABEL https://www.fda.gov/media/95283/download |
4 mg single, nasal dose: 4 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.68 ng × h/mL DRUG LABEL https://www.fda.gov/media/95283/download |
0.4 mg single, intramuscular dose: 0.4 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15 ng × h/mL DRUG LABEL https://www.fda.gov/media/95283/download |
8 mg single, nasal dose: 8 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28.2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28444856/ |
10 mg/kg single, nasal dose: 10 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.2 h DRUG LABEL https://www.fda.gov/media/95283/download |
0.4 mg single, intramuscular dose: 0.4 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.1 h DRUG LABEL https://www.fda.gov/media/95283/download |
8 mg single, nasal dose: 8 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.8 mg single, intramuscular Dose: 0.8 mg Route: intramuscular Route: single Dose: 0.8 mg Sources: |
healthy, 23.8 years (range: 22.6–25 years) Health Status: healthy Age Group: 23.8 years (range: 22.6–25 years) Sex: M+F Sources: |
|
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Disc. AE: Hypotension, Bradycardia... Other AEs: Nausea, Emesis... AEs leading to discontinuation/dose reduction: Hypotension (3 patients) Other AEs:Bradycardia (2 patients) Myoclonus (1 patient) Hypertension (1 patient) Nausea (32%) Sources: Emesis (5%) Seizures (5%) Headache (5%) Confusion (5%) Agitation (3%) |
8 mg single, intranasal Dose: 8 mg Route: intranasal Route: single Dose: 8 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | 1 patient Disc. AE |
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Myoclonus | 1 patient Disc. AE |
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Bradycardia | 2 patients Disc. AE |
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Hypotension | 3 patients Disc. AE |
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Agitation | 3% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Nausea | 32% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Confusion | 5% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Emesis | 5% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Headache | 5% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Seizures | 5% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
likely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
yes | |||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Antagonism by naloxone of morphine-induced single-dose dependence and antinociception in mice. | 1976 Dec |
|
The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. | 1992 Mar 20 |
|
The calcium antagonist diltiazem has antiarrhythmic effects which are mediated in the brain through endogenous opioids. | 1992 May |
|
[Experimental study on the effect of abstinence with herbal preparation qingjunyin]. | 1998 May |
|
Seizure and electroencephalographic changes in the newborn period induced by opiates and corrected by naloxone infusion. | 1999 Mar |
|
Morphine inhibits human microglial cell production of, and migration towards, RANTES. | 2000 |
|
Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns. | 2000 Apr |
|
The effect of spinal ibuprofen on opioid withdrawal in the rat. | 2000 Aug |
|
A peripheral, intracerebral, or intrathecal administration of an opioid receptor antagonist blocks illness-induced hyperalgesia in the rat. | 2000 Dec |
|
Phenytoin, midazolam, and naloxone protect against fentanyl-induced brain damage in rats. | 2000 Dec |
|
Methadone, ciprofloxacin, and adverse drug reactions. | 2000 Dec 16 |
|
Orphanin FQ/nociceptin inhibits morphine withdrawal. | 2000 Jan 14 |
|
Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. | 2000 Mar |
|
Hypertensive crisis and myocardial infarction following massive clonidine overdose. | 2000 May |
|
Systemic naloxone enhances cerebral blood flow in anesthetized morphine-dependent rats. | 2000 Nov 24 |
|
Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence. | 2000 Oct 15 |
|
Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. | 2000 Sep |
|
Opioid peptides alleviated while naloxone potentiated methamphetamine-induced striatal dopamine depletion in mice. | 2001 |
|
Effect of whole-body vibration in the vertical axis on cortisol and adrenocorticotropic hormone levels in piglets. | 2001 Apr |
|
Opioid peptides attenuate blood pressure increase in acute respiratory failure. | 2001 Apr |
|
Relief by naloxone of morphine-induced spasm of the sphincter of Oddi in a post-cholecystectomy patient. | 2001 Aug |
|
Opioid-induced hyperalgesia and incisional pain. | 2001 Jul |
|
Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. | 2001 Jun |
|
Morphine-induced dependence and sensitization are altered in mice deficient in AMPA-type glutamate receptor-A subunits. | 2001 Jun 15 |
|
Naloxone improves arterial blood pressure and hypoxic ventilatory depression, but not survival, of rats during acute hypoxia. | 2001 Mar |
|
Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. | 2001 May |
|
Effects of Ferula gummosa Boiss. fractions on morphine dependence in mice. | 2001 Sep |
|
Effect of naloxone-precipitated morphine withdrawal on CRH and vasopressin mRNA expression in the rat hypothalamic paraventricular nucleus. | 2002 Dec 6 |
|
The role of spinal neuropeptides and prostaglandins in opioid physical dependence. | 2002 May |
|
Cocaine/heroin induced rhabdomyolysis and ventricular fibrillation. | 2002 May |
|
Nicotine potentiation of morphine-induced catalepsy in mice. | 2002 May |
|
Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. | 2003 Jun |
|
Heroin addicts to receive CPR training and Narcan. | 2003 May |
|
Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. | 2003 May |
|
Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. | 2003 Nov |
|
Influence of sweet tasting solutions on opioid withdrawal. | 2004 Dec 15 |
|
Identification of UGT2B9*2 and UGT2B33 isolated from female rhesus monkey liver. | 2004 Jun 1 |
|
Magnesium influence on morphine--induced pharmacodependence in rats. | 2004 Mar |
|
Testosterone and luteinizing hormone responses to naloxone help predict sexual performance in rams. | 2004 Nov |
|
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. | 2004 Nov |
|
Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system. | 2004 Nov 19 |
|
Effects of L-745,870, a dopamine D4 receptor antagonist, on naloxone-induced morphine dependence in mice. | 2004 Oct |
|
Differential roles of peripheral and spinal endothelin receptors in the micturition reflex in rats. | 2004 Oct |
|
Rapid, transient, and dose-dependent expression of hsp70 messenger RNA in the rat brain after morphine treatment. | 2004 Summer |
|
[Combination of morphine with low-dose naloxone for intravenous patient-controlled analgesia]. | 2005 Apr |
|
Ventricular tachycardia following naloxone administration in an illicit drug misuse. | 2005 Aug |
|
[Effect of naloxone on expression of Bcl-2 protein and tumor necrosis factor-alpha in rats with acute myocardial ischemia/reperfusion injury]. | 2005 Jul |
|
The opioid fentanyl affects light input, electrical activity and Per gene expression in the hamster suprachiasmatic nuclei. | 2005 Jun |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. | 2005 Nov |
Sample Use Guides
Opioid Overdose–Known or Suspected: An initial dose of 0.4 mg to 2 mg of NARCAN may be administered intravenously. If the desired degree of counteraction and improvement in respiratory functions are not obtained, it may be repeated at two- to three-minute intervals. If no response is observed after 10 mg of NARCAN have been administered, the diagnosis of opioid-induced or partial opioid-induced toxicity should be questioned. Intramuscular or subcutaneous administration may be necessary if the intravenous route is not available.
Postoperative Opioid Depression: For the partial reversal of opioid depression following the use of opioids during surgery, smaller doses of NARCAN are usually sufficient. The dose of NARCAN should be titrated according to the patient’s response. For the initial reversal of respiratory depression, NARCAN should be injected in increments of 0.1 to 0.2 mg intravenously at two- to three-minute intervals to the desired degree of reversal, i.e., adequate ventilation and alertness without significant pain or discomfort. Larger than necessary dosage of NARCAN may result in significant reversal of analgesia and increase in blood pressure. Similarly, too rapid reversal may induce nausea, vomiting, sweating or circulatory stress.
Repeat doses of NARCAN may be required within one- to two-hour intervals depending upon the amount, type (i.e., short or long acting) and time interval since last administration of an opioid. Supplemental intramuscular doses have been shown to produce a longer lasting effect.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17624703
MDCKII-MDR1 assay. Stock solutions of Naloxone (20 mM) were prepared in 100% DMSO and then diluted to the final concentration of 10 mkM, in Dulbecco’s PBS. Naloxone were tested in both directions, apicalto-basolateral (A→B) and basolateral-to-apical (B→A), in duplicate. The ratio BA/AB >2 indicates an efflux phenomena. Permeability studies were conducted at 37 ◦C in incubator for 60 min. The monolayer integrity was evaluated by measuring the TransEpithelial Electrical Resistance (TEER) by using the Millicell-ERS system (Millipore Corporation) and it was considered integer if the resistancewas between 200 and 300 cm2. After the transport study the monolayer integrity was measured
in each well by adding a 0.02 mg/mL solution of lucifer yellow (LY); the test was conducted at 37 ◦C for 60 min, and the fluorescence (RFU) was measured at 485/535 nm.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:34:16 GMT 2025
by
admin
on
Mon Mar 31 17:34:16 GMT 2025
|
Record UNII |
5Q187997EE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/12/1057
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1010598
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
5Q187997EE
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | |||
|
m7717
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | |||
|
DTXSID90199452
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | |||
|
NALOXONE HYDROCHLORIDE DIHYDRATE
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | Description: A white or almost white powder. Solubility: Soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Narcotic antagonist. Storage: Naloxone hydrochloride should be kept in a tightly closed container, protected from light. Labelling: The designation on the container of Naloxone hydrochloride should state whether the substance is in the anhydrous form or is the dihydrate. Additional information: Even in the absence of light, Naloxone hydrochloride is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. It melts at about 177?C. | ||
|
100000089225
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | |||
|
51481-60-8
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | |||
|
SUB12168MIG
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | |||
|
5Q187997EE
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | |||
|
DBSALT001497
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY | |||
|
20112022
Created by
admin on Mon Mar 31 17:34:16 GMT 2025 , Edited by admin on Mon Mar 31 17:34:16 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|